Filtered By:
Education: Study
Therapy: Stem Cell Therapy
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 1233 results found since Jan 2013.
Complete Restoration of Motor Function in Acute Cerebral Stroke Treated with Allogeneic Human Umbilical Cord Blood Monocytes: Preliminary Results of a phase I Clinical Trial
Cell Transplant. 2021 Jan-Dec;30:9636897211067447. doi: 10.1177/09636897211067447.ABSTRACTStem cell therapy has been explored for the treatment of cerebral stroke. Several types of stem cells have been investigated to ensure the safety and efficacy in clinical trials.Cryopreserved umbilical cord blood (UCB) mononuclear cells (MNCs) obtained from healthy donors have a more stabilized quality, thereby ensuring a successful therapy. A phase I study was conducted on patients aged 45-80 years who sustained acute ischemic stroke. An UCB unit was obtained from a public cord blood bank based on ABO/Rh blood type, HLA matching scor...
Source: Cell Transplantation - December 23, 2021 Category: Cytology Authors: Tian-Kuo Lee Cheng-You Lu Sheng-Tzung Tsai Pao-Hui Tseng Yu-Chen Lin Shinn-Zong Lin Jonas C Wang Chih-Yang Huang Tsung-Lang Chiu Source Type: research
COVID-19-Induced Stroke and the Potential of Using Mesenchymal Stem Cells-Derived Extracellular Vesicles in the Regulation of Neuroinflammation
In this study, we have first described the advantages and disadvantages of neuroinflammation in the pathological evolution after IS and summarized the characteristics of neuroinflammation in COVID-19-related stroke. Then, we have discussed the potential benefit of MSC-EVs in the regulation of inflammatory responses after COVID-19-induced ischemic events.PMID:35025001 | PMC:PMC8755896 | DOI:10.1007/s10571-021-01169-1
Source: Cellular and Molecular Neurobiology - January 13, 2022 Category: Cytology Authors: Leyla Norouzi-Barough Amir Asgari Khosroshahi Ali Gorji Fariba Zafari Mohammad Shahverdi Shahraki Sadegh Shirian Source Type: research
Meta-Analysis: The Clinical Application of Autologous Adult Stem Cells in the Treatment of Stroke
CONCLUSION: Most of the trials were early phase studies that focused on safety rather than efficacy. Stem cells have demonstrated breakthrough results in the field of regenerative medicine. Therefore, study design could be improved in the future by enrolling a larger patient population and focusing more on localized delivery rather than intravenous transplantation. Trials should also introduce a more standardized method of analyzing and reporting clinical outcomes to achieve a better comparable outcome and possibly recognize the full potential that these cells have to offer.PMID:35002259 | PMC:PMC8721025 | DOI:10.2147/SCCAA.S344943
Source: Stem Cells and Cloning: Advances and Applications - January 10, 2022 Category: Stem Cells Authors: Noora Hassani Sebastien Taurin Sfoug Alshammary Source Type: research
Complete Restoration of Motor Function in Acute Cerebral Stroke Treated with Allogeneic Human Umbilical Cord Blood Monocytes: Preliminary Results of a phase I Clinical Trial
Cell Transplant. 2021 Jan-Dec;30:9636897211067447. doi: 10.1177/09636897211067447.ABSTRACTStem cell therapy has been explored for the treatment of cerebral stroke. Several types of stem cells have been investigated to ensure the safety and efficacy in clinical trials.Cryopreserved umbilical cord blood (UCB) mononuclear cells (MNCs) obtained from healthy donors have a more stabilized quality, thereby ensuring a successful therapy. A phase I study was conducted on patients aged 45-80 years who sustained acute ischemic stroke. An UCB unit was obtained from a public cord blood bank based on ABO/Rh blood type, HLA matching scor...
Source: Cell Transplantation - December 23, 2021 Category: Cytology Authors: Tian-Kuo Lee Cheng-You Lu Sheng-Tzung Tsai Pao-Hui Tseng Yu-Chen Lin Shinn-Zong Lin Jonas C Wang Chih-Yang Huang Tsung-Lang Chiu Source Type: research
Meta-Analysis: The Clinical Application of Autologous Adult Stem Cells in the Treatment of Stroke
CONCLUSION: Most of the trials were early phase studies that focused on safety rather than efficacy. Stem cells have demonstrated breakthrough results in the field of regenerative medicine. Therefore, study design could be improved in the future by enrolling a larger patient population and focusing more on localized delivery rather than intravenous transplantation. Trials should also introduce a more standardized method of analyzing and reporting clinical outcomes to achieve a better comparable outcome and possibly recognize the full potential that these cells have to offer.PMID:35002259 | PMC:PMC8721025 | DOI:10.2147/SCCAA.S344943
Source: Stem Cells and Cloning: Advances and Applications - January 10, 2022 Category: Stem Cells Authors: Noora Hassani Sebastien Taurin Sfoug Alshammary Source Type: research
Complete Restoration of Motor Function in Acute Cerebral Stroke Treated with Allogeneic Human Umbilical Cord Blood Monocytes: Preliminary Results of a phase I Clinical Trial
Cell Transplant. 2021 Jan-Dec;30:9636897211067447. doi: 10.1177/09636897211067447.ABSTRACTStem cell therapy has been explored for the treatment of cerebral stroke. Several types of stem cells have been investigated to ensure the safety and efficacy in clinical trials.Cryopreserved umbilical cord blood (UCB) mononuclear cells (MNCs) obtained from healthy donors have a more stabilized quality, thereby ensuring a successful therapy. A phase I study was conducted on patients aged 45-80 years who sustained acute ischemic stroke. An UCB unit was obtained from a public cord blood bank based on ABO/Rh blood type, HLA matching scor...
Source: Cell Transplantation - December 23, 2021 Category: Cytology Authors: Tian-Kuo Lee Cheng-You Lu Sheng-Tzung Tsai Pao-Hui Tseng Yu-Chen Lin Shinn-Zong Lin Jonas C Wang Chih-Yang Huang Tsung-Lang Chiu Source Type: research
Meta-Analysis: The Clinical Application of Autologous Adult Stem Cells in the Treatment of Stroke
CONCLUSION: Most of the trials were early phase studies that focused on safety rather than efficacy. Stem cells have demonstrated breakthrough results in the field of regenerative medicine. Therefore, study design could be improved in the future by enrolling a larger patient population and focusing more on localized delivery rather than intravenous transplantation. Trials should also introduce a more standardized method of analyzing and reporting clinical outcomes to achieve a better comparable outcome and possibly recognize the full potential that these cells have to offer.PMID:35002259 | PMC:PMC8721025 | DOI:10.2147/SCCAA.S344943
Source: Stem Cells and Cloning: Advances and Applications - January 10, 2022 Category: Stem Cells Authors: Noora Hassani Sebastien Taurin Sfoug Alshammary Source Type: research
Complete Restoration of Motor Function in Acute Cerebral Stroke Treated with Allogeneic Human Umbilical Cord Blood Monocytes: Preliminary Results of a phase I Clinical Trial
Cell Transplant. 2021 Jan-Dec;30:9636897211067447. doi: 10.1177/09636897211067447.ABSTRACTStem cell therapy has been explored for the treatment of cerebral stroke. Several types of stem cells have been investigated to ensure the safety and efficacy in clinical trials.Cryopreserved umbilical cord blood (UCB) mononuclear cells (MNCs) obtained from healthy donors have a more stabilized quality, thereby ensuring a successful therapy. A phase I study was conducted on patients aged 45-80 years who sustained acute ischemic stroke. An UCB unit was obtained from a public cord blood bank based on ABO/Rh blood type, HLA matching scor...
Source: Cell Transplantation - December 23, 2021 Category: Cytology Authors: Tian-Kuo Lee Cheng-You Lu Sheng-Tzung Tsai Pao-Hui Tseng Yu-Chen Lin Shinn-Zong Lin Jonas C Wang Chih-Yang Huang Tsung-Lang Chiu Source Type: research
Meta-Analysis: The Clinical Application of Autologous Adult Stem Cells in the Treatment of Stroke
CONCLUSION: Most of the trials were early phase studies that focused on safety rather than efficacy. Stem cells have demonstrated breakthrough results in the field of regenerative medicine. Therefore, study design could be improved in the future by enrolling a larger patient population and focusing more on localized delivery rather than intravenous transplantation. Trials should also introduce a more standardized method of analyzing and reporting clinical outcomes to achieve a better comparable outcome and possibly recognize the full potential that these cells have to offer.PMID:35002259 | PMC:PMC8721025 | DOI:10.2147/SCCAA.S344943
Source: Stem Cells and Cloning: Advances and Applications - January 10, 2022 Category: Stem Cells Authors: Noora Hassani Sebastien Taurin Sfoug Alshammary Source Type: research
Exosomal microRNAs as Potential Biomarkers and Therapeutic Agents for Acute Ischemic Stroke: New Expectations
The morbidity and mortality rates of ischemic stroke (IS) are very high, and IS constitutes one of the main causes of disability and death worldwide. The pathogenesis of ischemic stroke includes excitotoxicity, calcium overload, oxygen radical injury, inflammatory reactions, necrosis/apoptosis, destruction of the blood-brain barrier (BBB), and other pathologic processes. Recent studies have shown that exosomes are critical to the pathogenesis, diagnosis, and treatment of cerebral infarctions resulting from ischemic stroke; and there is growing interest in the role of exosomes and exosomal miRNAs in the diagnosis and treatm...
Source: Frontiers in Neurology - January 24, 2022 Category: Neurology Source Type: research
